Ascendis Pharma A/s insider trading

Every open-market purchase and sale by Ascendis Pharma A/s's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $777,068 5 trades by 2 insiders Insider sales, 5 years $5.5M 3 trades by 3 insiders

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.

Ascendis Pharma A/s insider open-market trades
Date	Insider	Trade	Shares	Price	Value	1M after	3M after	6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Ascendis Pharma A/s’s insiders pay?

From May 12, 2026 to September 9, 2026, 5 insiders reported 5 open-market purchases and 3 sales not made under a pre-set plan in Ascendis Pharma A/s. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on May 28, 2026 into $10,489 by November 2, 2026, +11.7% a year. It held shares 100% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $10,076 (+1.8% a year), and held throughout $10,076 (+1.8%).

Copying Ascendis Pharma A/s's insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Ascendis Pharma A/s's insiders from May 28, 2026, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 100% of the time.

Ascendis Pharma A/s: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
Bienaime Jean Jacques	Director	3	—	—	0	—	August 18, 2026
Smith Scott Thomas	EVP & Chief Financial Officer	2	—	—	0	—	June 2, 2026
Bodenhoff Mads	SVP & PAO	0	—	—	1	—	September 9, 2026
Holtug Lars	Director	0	—	—	1	—	September 3, 2026
Jensen Flemming Steen	See Remarks	0	—	—	1	—	May 12, 2026

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Ascendis Pharma A/s

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Ascendis Pharma A/s in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. One company's history is too short to judge by; the test across every company is the better guide.

Month	Crowd	3 months on, vs S&P 500	6 months	12 months
June 30, 2026	2 buying	−17.1%	not yet	not yet

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Ascendis Pharma A/s · Funds · Politicians